Health Care [ 6/12 ] | Biotechnology [ 43/73 ]
NASDAQ | Common Stock
Grifols,S. A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties.
In addition, the company offers Yimmugo IDP, an immunology drug; Yimmugo PTI, a hematology drug; and Prolastin vials, a pulmonology drug.
Further, it develops Xembify Pre-filled syringes, Gamunex Bags, and FlexBag; Xembify Biweekly dosing, Fibrinogen, and VISTASEAL; Prolastin-C AADT and Fostamatinib; Xembify " CLL, Albumina 20% and 5%, and Trimodulin; Alfa-1 AT 15%, GRF6019, GRF6021, Aßvac402, AKST4290, and AKST4290; GIGA 2339 and GIGA564; and recIG, Alfa-1 AT - in non-cystic fibrosis bronchiectasis, and OSIG that are in pre-clinical stage.
It has collaboration agreements with Canadian Blood Services to supply grains of Immunoglobulin.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 29, 25 | 0.22 Increased by +48.67% | 0.22 Decreased by -0.04% |
| May 12, 25 | 0.09 Increased by +32.00% | 0.16 Decreased by -43.86% |
| Feb 26, 25 | 0.11 Decreased by -22.79% | 0.23 Decreased by -52.67% |
| Nov 7, 24 | 0.17 Increased by +54.55% | 0.24 Decreased by -29.17% |
| Jul 30, 24 | 0.15 Decreased by -9.04% | 0.21 Decreased by -28.57% |
| May 16, 24 | 0.07 Increased by +59.82% | 0.15 Decreased by -53.33% |
| Feb 29, 24 | 0.14 Increased by +118.41% | 0.22 Decreased by -36.36% |
| Nov 2, 23 | 0.11 Increased by +N/A% | 0.22 Decreased by -50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 1.89 B Increased by +4.03% | 117.06 M Increased by +688.78% | Increased by +6.19% Increased by +658.24% |
| Mar 31, 25 | 1.79 B Increased by +9.85% | 59.73 M Increased by +178.84% | Increased by +3.34% Increased by +153.84% |
| Dec 31, 24 | 1.98 B Increased by +11.66% | 68.97 M Increased by +23.17% | Increased by +3.49% Increased by +10.31% |
| Sep 30, 24 | 1.79 B Increased by +12.24% | 51.69 M Decreased by -13.19% | Increased by +2.88% Decreased by -22.65% |
| Jun 30, 24 | 1.82 B Increased by +9.28% | 14.84 M Decreased by -75.28% | Increased by +0.82% Decreased by -77.38% |
| Mar 31, 24 | 1.63 B Increased by +5.38% | 21.42 M Increased by +302.12% | Increased by +1.32% Increased by +291.80% |
| Dec 31, 23 | 1.77 B Increased by +3.32% | 55.99 M Increased by +178.99% | Increased by +3.16% Increased by +170.03% |
| Sep 30, 23 | 1.60 B Increased by +3.66% | 59.54 M Increased by +33.63% | Increased by +3.73% Increased by +28.91% |